Ending Isolation and Precautions for People with COVID-19: Interim Guidance

Updates as of January 14, 2022

As of January 14, 2022

• Updated guidance to reflect new recommendations for isolation for people with COVID-19.
• Added new recommendations for duration of isolation for people with COVID-19 who are moderately or severely immunocompromised.

View Previous Updates

See more: Covid 19 patient

Key Points for Healthcare Professionals

• Children and adults with mild, symptomatic COVID-19: Isolation can end at least 5 days after symptom onset and after fever ends for 24 hours (without the use of fever-reducing medication) and symptoms are improving, if these people can continue to properly wear a well-fitted mask around others for 5 more days after the 5-day isolation period. Day 0 is the first day of symptoms.
• People who are infected but asymptomatic (never develop symptoms): Isolation can end at least 5 days after the first positive test (with day 0 being the date their specimen was collected for the positive test), if these people can continue to wear a properly well-fitted mask around others for 5 more days after the 5-day isolation period. However, if symptoms develop after a positive test, their 5-day isolation period should start over (day 0 changes to the first day of symptoms).
• People who have moderate COVID-19 illness: Isolate for 10 days.
• People who are severely ill (i.e., requiring hospitalization, intensive care, or ventilation support): Extending the duration of isolation and precautions to at least 10 days and up to 20 days after symptom onset, and after fever ends (without the use of fever-reducing medication) and symptoms are improving, may be warranted.
• People who are moderately or severely immunocompromised might have a longer infectious period: Extend isolation to 20 or more days (day 0 is the first day of symptoms or a positive viral test). Use a test-based strategy and consult with an infectious disease specialist to determine the appropriate duration of isolation and precautions.
• Recovered patients: Patients who have recovered from COVID-19 can continue to have detectable SARS-CoV-2 RNA in upper respiratory specimens for up to 3 months after illness onset. However, replication-competent virus has not been reliably recovered from such patients, and they are not likely infectious.

On This Page

• Recommendations for Ending Isolation
• Assessment for Duration of Isolation
• Key Findings from Transmission Literature

• Limitations of Current Evidence
• References
• Previous Updates

To prevent SARS-CoV-2 transmission, see CDC’s recommended prevention strategies. For details on when to get tested for COVID-19, see Test for Current Infection.

Recommendation for Ending Isolation

For people who are mildly ill with a laboratory-confirmed SARS-CoV-2 infection and not moderately or severely immunocompromised:

• Isolation can be discontinued at least 5 days after symptom onset (day 1 through day 5 after symptom onset, with day 0 being the first day of symptoms), and after resolution of fever for at least 24 hours (without the use of fever-reducing medications) and with improvement of other symptoms.
• Loss of taste and smell may persist for weeks or months after recovery and need not delay the end of isolation​.
• These people should continue to properly wear a well-fitted mask around others at home and in public for 5 additional days (day 6 through day 10 after symptom onset) after the 5-day isolation period.
• People who cannot properly wear a mask, including children < 2 years of age and people of any age with certain disabilities, should isolate for 10 days. In certain high-risk congregate settings that have high risk of secondary transmission and where it is not feasible to cohort people, CDC recommends a 10-day isolation period for residents.

More details: What We Know About Quarantine and Isolation

For people who test positive, are asymptomatic (never develop symptoms) and not moderately or severely immunocompromised:

• Isolation can be discontinued at least 5 days after the first positive viral test (day 0 through day 5, with day 0 being the date their specimen was collected for the positive test).
• These people should continue to properly wear a well-fitted mask around others at home and in public for 5 additional days (day 6 through day 10) after the 5-day isolation period. Day 0 is the date their specimen was collected for the positive test and day 1 is the first full day after the specimen was collected for the positive test.
• If a person develops symptoms after testing positive, their 5-day isolation period should start over (day 0 changes to the first day of symptoms).
• People who cannot properly wear a mask, including children < 2 years of age and people of any age with certain disabilities, should isolate for 10 days. In certain high-risk congregate settings that have high risk of secondary transmission and where it is not feasible to cohort people, CDC recommends a 10-day isolation period for residents.

More details: What We Know About Quarantine and Isolation

For people who are moderately ill and not moderately or severely immunocompromised:

• Isolation and precautions can be discontinued 10 days after symptom onset (day 1 through day 10, with day 0 being the first day of symptoms).

View more: Achieving 70% COVID-19 Immunization Coverage by Mid-2022

For people who are severely ill and not moderately or severely immunocompromised:

• A test-based strategy can be considered in consultation with infectious disease experts.
• Some people with severe illness (e.g., requiring hospitalization, intensive care, or ventilation support) may produce replication-competent virus beyond 10 days that may warrant extending the duration of isolation and precautions for up to 20 days after symptom onset (with day 0 being the first day of symptoms) and after resolution of fever for at least 24 hours (without the use of fever-reducing medications) and improvement of other symptoms.

For people who are moderately or severely immunocompromised (regardless of COVID-19 symptoms or severity):

• Moderately or severely immunocompromised patients may produce replication-competent virus beyond 20 days. For these people, CDC recommends an isolation period of at least 20 days, and ending isolation in conjunction with a test-based strategy and consultation with an infectious disease specialist to determine the appropriate duration of isolation and precautions.
• The criteria for the test-based strategy are:
  • Results are negative from at least two consecutive respiratory specimens collected ≥ 24 hours apart (total of two negative specimens) tested using an antigen test or nucleic acid amplification test.
  • Also, if a moderately or severely immunocompromised patient with COVID-19 was symptomatic, there should be resolution of fever for at least 24 hours (without the use of fever-reducing medication) and improvement of other symptoms. Loss of taste and smell may persist for weeks or months after recovery and need not delay the end of isolation​.
• Re-testing for SARS-CoV-2 infection is suggested if symptoms worsen or return after ending isolation and precautions based on this test-based strategy for moderately or severely immunocompromised people.(1)
• If a patient has persistently positive nucleic acid amplification tests beyond 30 days, additional testing could include molecular studies (e.g., genomic sequencing) or viral culture, in consultation with an infectious disease specialist.
• For the purposes of this guidance, moderate to severely immunocompromising conditions include, but might not be limited to, those defined in the interim clinical considerations for people with moderate to severe immunocompromise due to a medical condition or receipt of immunosuppressive medications or treatments.
  • Other factors, such as end-stage renal disease, likely pose a lower degree of immunocompromise, and there might not be a need to follow the recommendations for those with moderate to severe immunocompromise.
  • Ultimately, the degree of immunocompromise for the patient is determined by the treating provider, and preventive actions should be tailored to each patient and situation.

More details: COVID-19 Quarantine and Isolation and What We Know About Quarantine and Isolation

Top of Page

Assessment for Duration of Isolation

Available data suggest that patients with mild-to-moderate COVID-19 remain infectious no longer than 10 days after symptom onset. More information is available at What We Know About Quarantine and Isolation.

Most patients with more severe-to-critical illness likely remain infectious no longer than 20 days after symptom onset.

There have been numerous reports of moderately or severely immunocompromised people shedding replication-competent virus beyond 20 days.(examples: 1-33) A higher SARS-CoV-2 viral load and longer duration of infection among moderately or severely immunocompromised people may favor emergence of SARS-CoV-2 variants.(5,14,19,30,34,35) Strategies that reduce SARS-CoV-2 transmission to and from people at increased risk of long-term infections could slow the emergence and spread of new variants.(34,35)

Patients who have recovered from COVID-19 can continue to have detectable SARS-CoV-2 RNA in upper respiratory specimens for up to 3 months after illness onset in concentrations considerably lower than during illness; however, replication-competent virus has not been reliably recovered from such patients, and they are not likely infectious. The circumstances that result in persistently detectable SARS-CoV-2 RNA have yet to be determined. Studies have not found evidence that clinically recovered adults with persistence of viral RNA have transmitted SARS-CoV-2 to others. These findings strengthen the justification for relying on a symptom-based rather than test-based strategy for ending isolation of most patients.

Top of Page

Key Findings from Transmission Literature

1. Concentrations of SARS-CoV-2 RNA in upper respiratory specimens decline after onset of symptoms.(36-39, 40-43) Infectiousness peaks around one day before symptom onset and declines within a week of symptom onset, with an average period of infectiousness and risk of transmission between 2-3 days before and 8 days after symptom onset.(42,44)
2. Several studies have found similar concentrations of SARS-CoV-2 RNA in upper respiratory specimens from children and adults.(45-52)
   • To date, most studies of SARS-CoV-2 transmission have found that children and adults have a similar risk of transmitting SARS-CoV-2 to others.
   • One study reported that children were more likely to transmit SARS-CoV-2 than adults >60 years old.(53)
3. Certain SARS-CoV-2 variants of concern are more transmissible than the wild type virus or other variants, resulting in higher rates of infection. For example, people infected with the Delta variant, including people who are up to date with their vaccines with symptomatic breakthrough infections, can transmit infection to others. However, like other variants, the amount of virus produced by Delta breakthrough infections in people who are up to date with their vaccines decreases faster than in people who are not up to date with their vaccines.
4. The likelihood of recovering replication-competent (infectious) virus is very low after 10 days from onset of symptoms, except in people who have severe COVID-19 or who are moderately or severely immunocompromised.
   • For patients with mild COVID-19 who are not moderately or severely immunocompromised, replication-competent virus has not been recovered after 10 days following symptom onset for most patients.(38,39,54-58) With the recommended shorter isolation period for asymptomatic and mildly ill people with COVID-19, it is critical that people continue to properly wear well-fitted masks and take additional precautions for 5 days after leaving isolation.(59,60) Modeling data suggest that close to one-third of people remain infectious after day 5 and can potentially transmit the virus.(61) Outliers exist; in one case report, an adult with mild illness provided specimens that yielded replication-competent virus for up to 18 days after symptom onset.(62)
   • Recovery of replication-competent virus between 10 and 20 days after symptom onset has been reported in some adults with severe COVID-19; some of these people were immunocompromised.(37) However, in this series of patients, it was estimated that 88% and 95% of their specimens no longer yielded replication-competent virus after 10 and 15 days, respectively, following symptom onset.
   • Detection of sub-genomic SARS-CoV-2 RNA or recovery of replication-competent virus has been reported in moderately or severely immunocompromised patients beyond 20 days, and as long as >140 days after a positive SARS-CoV-2 test result.(examples: 1-33) Immunocompromising conditions that have been associated with shedding of replication-competent virus beyond 20 days include active treatment for solid tumor and hematologic malignancies, solid organ transplant and taking immunosuppressive therapy, receipt of CAR-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppression therapy), moderate or severe primary immunodeficiency, and active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and other biologic agents that are immunosuppressive or immunomodulatory.(examples: 1-33)
   • Prolonged detection of replication-competent virus may be associated with other factors. For example, a 13-year-old immunocompetent male was hospitalized for injuries received in a motor vehicle crash. He required intubation, developed pulmonary infiltrates, and tested positive for SARS-CoV-2. Viral cultures of upper and lower respiratory tract specimens were positive for SARS-CoV-2 on days 47 and 54 of his hospitalization.(63)
5. The risk of SARS-CoV-2 transmission to others varies based upon several factors including time after symptom onset, virus variant, virus levels in the upper respiratory tract, and disease status (asymptomatic, pre-symptomatic, or symptomatic).
   • In a large contact tracing study, no contacts developed SARS-CoV-2 infection if their exposure to a COVID-19 case patient occurred 6 days or more after the case patient’s symptom onset.(64)
   • One study reported that 59% of SARS-CoV-2 transmission originated from index cases that were asymptomatic or pre-symptomatic.(65)
   • A meta-analysis found that the secondary attack rate for asymptomatic (never develop symptoms) index cases was 1.9%, but was 9.3% for pre-symptomatic and 13.6% for symptomatic index cases.(66) Therefore, people with SARS-CoV-2 infection without symptoms pose a transmission risk and should isolate based upon CDC’s quarantine and isolation recommendations.
6. People who have recovered from COVID-19 may have prolonged detection of SARS-CoV-2 RNA.(67) However, prolonged detection of viral RNA does not necessarily mean that such people are a transmission risk.(68) Studies of patients who were hospitalized and recovered indicate that SARS-CoV-2 RNA can be detected in upper respiratory tract specimens for up to 3 months (12 weeks) after symptom onset.(58,62,69)
   • Investigation of 285 “persistently SARS-CoV-2 RNA positive” adults, which included 126 adults who had developed recurrent symptoms, found no secondary infections among 790 contacts. Efforts to isolate replication-competent virus were attempted for 108 of these 285 case patients, and SARS-CoV-2 was not recovered in viral culture from any of the 108 specimens.(58)
7. The probability of SARS-CoV-2 reinfection may increase with time after recovery, consistent with other human coronaviruses, because of waning immunity and the possibility of exposure to viral variants.(70-78) The risk of reinfection also depends on host susceptibility, vaccination status, and the likelihood of re-exposure to infectious cases of COVID-19. Continued widespread transmission makes it more likely that reinfections will occur.
8. Loss of taste and smell may continue for weeks or months after recovery.(79) The presence of these symptoms does not mean that the isolation period must be extended.

Limitations of Current Evidence

• Studies referenced in this document may have differences compared to the current epidemiology of COVID-19 in the United States. Specifically, many of these references involve non-US populations, homogenous populations, virus transmission prior to the availability of vaccination for COVID-19, and infection prior to the known circulation of SARS-CoV-2 current variants of concern, such as the Delta or Omicron variant. More studies are needed to fully understand virus transmission related to the Delta variant, Omicron variant, and other SARS-CoV-2 variants among people who are up to date with their vaccines.
• Studies have used viral culture to attempt to grow SARS-CoV-2 from clinical samples from patients who tested positive for SARS-CoV-2 to determine infectiousness. Because viral culture must be done in very specialized laboratories, these studies are more limited in number compared to studies using other test methods to detect SARS-CoV-2 infection.
• Many studies that assessed the duration of SARS-CoV-2 infectiousness have been conducted in adults. More studies are needed, especially in children with SARS-CoV-2 infection.
• More data are needed to understand the frequency and duration of infectious SARS-CoV-2 shedding among the spectrum of mild to severely immunocompromised people, including both asymptomatic and symptomatic people.
• More data are needed to fully understand the risk of recovery of replication-competent virus in people with severe COVID-19. There was variation in how studies defined severe illness with COVID-19. Some studies defined severe disease as cases requiring hospitalization or mechanical ventilation while other researchers used the definition of severityexternal icon from the COVID-19 Treatment Guidelines published by National Institutes of Health (NIH).

Top of Page

References

See All References

1. Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. J Infect Dis. Sep 1 2020;222(7):1103-1107. doi:10.1093/infdis/jiaa446external icon
2. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. New England Journal of Medicine. 2020;383(26):2586-2588. doi:10.1056/NEJMc2031670external icon
3. Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020/12/23/ 2020;183(7):1901-1912.e9. doi:https://doi.org/10.1016/j.cell.2020.10.049external icon
4. Baang JH, Smith C, Mirabelli C, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. The Journal of Infectious Diseases. 2020;223(1):23-27. doi:10.1093/infdis/jiaa666external icon
5. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine. 2020;383(23):2291-2293. doi:10.1056/NEJMc2031364external icon
6. Tarhini H, Recoing A, Bridier-nahmias A, et al. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. The Journal of Infectious Diseases. 2021;223(9):1522-1527. doi:10.1093/infdis/jiab075external icon

1. Ferrari A, Trevenzoli M, Sasset L, et al. Prolonged SARS-CoV-2-RNA Detection from Nasopharyngeal Swabs in an Oncologic Patient: What Impact on Cancer Treatment? Curr Oncol. Feb 8 2021;28(1):847-852. doi:10.3390/curroncol28010083external icon
2. Abdul-Jawad S, Baù L, Alaguthurai T, et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. Feb 8 2021;39(2):257-275.e6. doi:10.1016/j.ccell.2021.01.001external icon
3. Leung WF, Chorlton S, Tyson J, et al. COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report. Int J Infect Dis. Jan 2022;114:178-182. doi:10.1016/j.ijid.2021.10.045external icon
4. Truong TT, Ryutov A, Pandey U, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. EBioMedicine. May 2021;67:103355. doi:10.1016/j.ebiom.2021.103355external icon
5. Martinot M, Jary A, Fafi-Kremer S, et al. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. Clin Infect Dis. Oct 5 2021;73(7):e1762-e1765. doi:10.1093/cid/ciaa1474external icon
6. Truffot A, Andréani J, Le Maréchal M, et al. SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy. Emerging infectious diseases. Oct 2021;27(10):2725-2728. doi:10.3201/eid2710.211509external icon
7. Karataş A, İnkaya A, Demiroğlu H, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci. Oct 2020;59(5):102871. doi:10.1016/j.transci.2020.102871external icon
8. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021/04/01 2021;592(7853):277-282. doi:10.1038/s41586-021-03291-ypdf iconexternal icon
9. Khatamzas E, Rehn A, Muenchhoff M, et al. Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. medRxiv. 2021:2021.01.10.20248871. doi:10.1101/2021.01.10.20248871external icon
10. Yasuda H, Mori Y, Chiba A, et al. Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections. Clin Lymphoma Myeloma Leuk. 2021;21(10):e810-e816. doi:10.1016/j.clml.2021.07.004external icon
11. Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. Nov 12 2020;136(20):2290-2295. doi:10.1182/blood.2020008423external icon
12. Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. Feb 2021;27(2):387-389. doi:10.1016/j.jiac.2020.12.001external icon
13. Nussenblatt V, Roder AE, Das S, et al. Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. medRxiv. Oct 5 2021;doi:10.1101/2021.10.02.21264267external icon
14. Jassem J, Marek-Trzonkowska NM, Smiatacz T, et al. Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report. Int J Mol Sci. Oct 10 2021;22(20)doi:10.3390/ijms222010934external icon
15. Drouin AC, Theberge MW, Liu SY, et al. Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. Viruses. Jun 23 2021;13(7)doi:10.3390/v13071202external icon
16. Hensley MK, Bain WG, Jacobs J, et al. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clin Infect Dis. Aug 2 2021;73(3):e815-e821. doi:10.1093/cid/ciab072external icon
17. Malsy J, Veletzky L, Heide J, et al. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. Dec 6 2021;73(11):e4020-e4024. doi:10.1093/cid/ciaa1637external icon
18. Gibson EG, Pender M, Angerbauer M, et al. Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis. Open Forum Infect Dis. Jul 2021;8(7):ofab176. doi:10.1093/ofid/ofab176external icon
19. Lacson E, Jr., Weiner D, Majchrzak K, et al. Prolonged Live SARS-CoV-2 Shedding in a Maintenance Dialysis Patient. Kidney Med. Mar-Apr 2021;3(2):309-311. doi:10.1016/j.xkme.2020.12.001external icon
20. Marinelli T, Ferreira VH, Ierullo M, et al. Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients. Transplantation. Oct 1 2021;105(10):2175-2183. doi:10.1097/tp.0000000000003860external icon
21. Shingare A, Bahadur MM, Raina S. COVID-19 in recent kidney transplant recipients. Am J Transplant. Nov 2020;20(11):3206-3209. doi:10.1111/ajt.16120external icon
22. Wei L, Liu B, Zhao Y, Chen Z. Prolonged shedding of SARS-CoV-2 in an elderly liver transplant patient infected by COVID-19: a case report. Ann Palliat Med. Jun 2021;10(6):7003-7007. doi:10.21037/apm-20-996external icon
23. Theodore DA, Greendyke WG, Miko B, et al. Cycle Thresholds Among Solid Organ Transplant Recipients Testing Positive for SARS-CoV-2. Transplantation. Jul 1 2021;105(7):1445-1448. doi:10.1097/tp.0000000000003695external icon
24. Weigang S, Fuchs J, Zimmer G, et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun. Nov 4 2021;12(1):6405. doi:10.1038/s41467-021-26602-3external icon
25. Zhu L, Gong N, Liu B, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. Eur Urol. Jun 2020;77(6):748-754. doi:10.1016/j.eururo.2020.03.039external icon
26. Keitel V, Bode JG, Feldt T, et al. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure. Front Immunol. 2021;12:645989. doi:10.3389/fimmu.2021.645989external icon
27. Delgado-Fernández M, García-Gemar GM, Fuentes-López A, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature. Enferm Infecc Microbiol Clin (Engl Ed). Feb 11 2021;doi:10.1016/j.eimc.2021.01.013external icon
28. Van Egeren D, Novokhodko A, Stoddard M, et al. Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure. Scientific Reports. 2021/11/19 2021;11(1):22630. doi:10.1038/s41598-021-02148-8external icon
29. COVID-19 Science Update released: December 3, 2021 Edition 115. daypg.com/library/covid19/12032021_covidupdate.html
30. Kujawski SA, Wong KK, Collins JP, et al. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nature Medicine. 2020/06/01 2020;26(6):861-868. doi:10.1038/s41591-020-0877-5external icon
31. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nature Communications. 2021/01/11 2021;12(1):267. doi:10.1038/s41467-020-20568-4external icon

1. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020/05/01 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-xexternal icon
2. Owusu D, Pomeroy MA, Lewis NM, et al. Persistent SARS-CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19. The Journal of Infectious Diseases. 2021;doi:10.1093/infdis/jiab107external icon
3. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-1494. doi:10.1001/jama.2020.3204external icon
4. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine. 2020;382(12):1177-1179. doi:10.1056/NEJMc2001737external icon
5. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Annals of internal medicine. Jan 2021;174(1):69-79. doi:10.7326/m20-5008external icon
6. Weinbergerova B, Mayer J, Hrabovsky S, et al. COVID-19’s natural course among ambulatory monitored outpatients. Sci Rep. May 12 2021;11(1):10124. doi:10.1038/s41598-021-89545-1external icon
7. Peeling RW, Heymann DL, Teo Y-Y, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. The Lancet. 2021/12/20/ 2021;doi:https://doi.org/10.1016/S0140-6736(21)02346-1external icon
8. Madera S, Crawford E, Langelier C, et al. Nasopharyngeal SARS-CoV-2 viral loads in young children do not differ significantly from those in older children and adults. Sci Rep. Feb 4 2021;11(1):3044. doi:10.1038/s41598-021-81934-wexternal icon
9. Hurst JH, Heston SM, Chambers HN, et al. SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clin Infect Dis. Nov 3 2020;doi:10.1093/cid/ciaa1693external icon
10. Maltezou HC, Magaziotou I, Dedoukou X, et al. Children and Adolescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads. Pediatr Infect Dis J. Dec 2020;39(12):e388-e392. doi:10.1097/inf.0000000000002899external icon
11. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. Aug 2020;25(32)doi:10.2807/1560-7917.Es.2020.25.32.2001483external icon
12. L’Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerging infectious diseases. Oct 2020;26(10):2494-2497. doi:10.3201/eid2610.202403
13. Baggio S, L’Huillier AG, Yerly S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of Children and Adults With Early Acute Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. Jul 1 2021;73(1):148-150. doi:10.1093/cid/ciaa1157external icon
14. Bellon M, Baggio S, Bausch FJ, et al. SARS-CoV-2 viral load kinetics in symptomatic children, adolescents and adults. Clin Infect Dis. May 5 2021;doi:10.1093/cid/ciab396external icon

1. Xu CLH, Raval M, Schnall JA, Kwong JC, Holmes NE. Duration of Respiratory and Gastrointestinal Viral Shedding in Children With SARS-CoV-2: A Systematic Review and Synthesis of Data. Pediatr Infect Dis J. Sep 2020;39(9):e249-e256. doi:10.1097/inf.0000000000002814external icon
2. Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infect Dis. 2021 May;21(5):617-628. doi: 10.1016/S1473-3099(20)30981-6.external icon

1. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. New England Journal of Medicine. 2020;382(22):2081-2090. doi:10.1056/NEJMoa2008457external icon
2. Bullard J, Dust K, Funk D, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. Clinical Infectious Diseases. 2020;71(10):2663-2666. doi:10.1093/cid/ciaa638external icon
3. Young B, Ong S, Ng L, Anderson D, Chia W, Chia P. Immunological and Viral Correlates of COVID-19 Disease Severity: A Prospective Cohort Study of the First 100 Patients in Singapore (4/15/2020). Available at SSRN daypg.comrnal icon
4. Lu J, Peng J, Xiong Q, et al. Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. EBioMedicine. 2020/09/01/ 2020;59:102960. doi:https://doi.org/10.1016/j.ebiom.2020.102960external icon
5. Korea Centers for Disease Control and Prevention. Findings from Investigation and Analysis of re-positive cases. May 19, 2020. Accessed May 19, 2020. daypg.com/board/board.es?mid=a30402000000&bid=0030external icon
6. CDC. Science Brief: Community Use of Masks to Control the Spread of SARS-CoV-2. daypg.com/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html
7. Japan National Institute of Infectious Diseases and Disease Control and Prevention Center, National Center for Global Health and Medicine. Active epidemiological investigation on SARS-CoV-2 infection caused by Omicron variant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period. 2022. daypg.com/niid/en/2019-ncov-e/10884-covid19-66-en.htmlexternal icon

1. Bays D, Whiteley T, Pindar M, et al. Mitigating isolation: The use of rapid antigen testing to reduce the impact of self-isolation periods. medRxiv. 2021:2021.12.23.21268326. doi:10.1101/2021.12.23.21268326pdf iconexternal icon
2. Liu W-D, Chang S-Y, Wang J-T, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. Journal of Infection. 2020/08/01/ 2020;81(2):318-356. doi:https://doi.org/10.1016/j.jinf.2020.03.063external icon
3. Sahbudak Bal Z, Ozkul A, Bilen M, Kurugol Z, Ozkinay F. The Longest Infectious Virus Shedding in a Child Infected With the G614 Strain of SARS-CoV-2. Pediatr Infect Dis J. Jul 1 2021;40(7):e263-e265. doi:10.1097/inf.0000000000003158external icon
4. Cheng H-Y, Jian S-W, Liu D-P, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA Internal Medicine. 2020;180(9):1156-1163. doi:10.1001/jamainternmed.2020.2020external icon
5. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Network Open. 2021;4(1):e2035057-e2035057. doi:10.1001/jamanetworkopen.2020.35057external icon
6. Thompson HA, Mousa A, Dighe A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. Clin Infect Dis. Aug 2 2021;73(3):e754-e764. doi:10.1093/cid/ciab100external icon
7. Quicke K, Gallichotte E, Sexton N, et al. Longitudinal Surveillance for SARS-CoV-2 RNA Among Asymptomatic Staff in Five Colorado Skilled Nursing Facilities: Epidemiologic, Virologic and Sequence Analysis. medRxiv. 2020:2020.06.08.20125989. doi:10.1101/2020.06.08.20125989external icon
8. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? Clin Infect Dis. Apr 26 2021;72(8):1467-1474. doi:10.1093/cid/ciaa1249external icon
9. Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. Journal of Medical Virology. 2020;92(11):2286-2287. doi:https://doi.org/10.1002/jmv.25952external icon
10. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021:2021.01.18.427166. doi:10.1101/2021.01.18.427166external icon
11. Zucman N, Uhel F, Descamps D, Roux D, Ricard J-D. Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2. Clinical Infectious Diseases. 2021;doi:10.1093/cid/ciab129external icon
12. Harrington D, Kele B, Pereira S, et al. Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01. Clinical Infectious Diseases. 2021;doi:10.1093/cid/ciab014external icon
13. Resende PC, Bezerra JF, Teixeira Vasconcelos RH, et al. Severe Acute Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with Reinfection Case, Brazil, June-October 2020. Emerging infectious diseases. 2021;27(7):1789-1794. doi:10.3201/eid2707.210401external icon
14. Nonaka CKV, Franco MM, Gräf T, et al. Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. Emerging infectious diseases. 2021;27(5):1522-1524. doi:10.3201/eid2705.210191external icon
15. Naveca F, da Costa C, Nascimento V, et al. SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P. 1 in Amazonas, Brazil. virological org. 2021external icon
16. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet. 2021/02/06/ 2021;397(10273):452-455. doi:https://doi.org/10.1016/S0140-6736(21)00183-5external icon
17. Voloch CM, Silva F Rd, de Almeida LGP, et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. medRxiv. 2020:2020.12.23.20248598. doi:10.1101/2020.12.23.20248598external icon
18. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 b. 1.1. 7 lineage—united states, december 29, 2020-january 12, 2021. Morbidity and Mortality Weekly Report. 2021;70(3):95.
19. Otte MS, Bork M-L, Zimmermann PH, Klussmann JP, Luers JC. Persisting olfactory dysfunction improves in patients 6 months after COVID-19 disease. Acta Oto-Laryngologica. 2021/06/01 2021;141(6):626-629. doi:10.1080/00016489.2021.1905178external icon

Previous Updates

Updates from Previous Content: Ending Isolation and Precautions Webpage

As of September 14, 2021

• Combined guidance on ending isolation and precautions for adults with COVID-19 and ending home isolation webpages.
• Included evidence for expanding recommendations to include children.
• Edited to improve readability

View more: Taylor Swift and Conor Kennedys Whirlwind Romance: A Look Back at Their Relationship Timeline

As of February 18, 2021

• Some severely immunocompromised persons with COVID-19 may remain infectious beyond 20 days after their symptoms began and require additional SARS-CoV-2 testing and consultation with infectious diseases specialists and infection control experts.

As of February 13, 2021

• Added new evidence and recommendations for duration of isolation and precautions for severely immunocompromised adults.
• Added information on recent reports in adults of reinfection with SARS-CoV-2 variant viruses.

Updates from Previous Ending Home Isolation Webpage Content

As of February 18, 2021

• Some severely immunocompromised persons with COVID-19 may remain infectious beyond 20 days after their symptoms began and require additional SARS-CoV-2 testing and consultation with infectious diseases specialists and infection control experts.

Updates as of July 20, 2020

• A test-based strategy is no longer recommended to determine when to discontinue home isolation, except in certain circumstances.
• Symptom-based criteria were modified as follows:
  • Changed from “at least 72 hours” to “at least 24 hours” have passed since last fever without the use of fever-reducing medications.
  • Changed from “improvement in respiratory symptoms” to “improvement in symptoms” to address expanding list of symptoms associated with COVID-19.
• For patients with severe illness, duration of isolation for up to 20 days after symptom onset may be warranted. Consider consultation with infection control experts.
• For persons who never develop symptoms, isolation and other precautions can be discontinued 10 days after the date of their first positive RT-PCR test for SARS-CoV-2 RNA.

Updates as of July 17, 2020

• Symptom-based criteria were modified as follows:
  • Changed from “at least 72 hours” to “at least 24 hours” have passed since last fever without the use of fever-reducing medications
  • Changed from “improvement in respiratory symptoms” to “improvement in symptoms” to address expanding list of symptoms associated with COVID-19

Updates as of May 29, 2020

Added information around the management of persons who may have prolonged viral shedding after recovery.

Updates as of May 3, 2020

• Changed the name of the ‘non-test-based strategy’ to the ‘symptom-based strategy’ for those with symptoms. Added a ‘time-based strategy’ and named the ‘test-based strategy’ for asymptomatic persons with laboratory-confirmed COVID-19. Extended the home isolation period from 7 to 10 days since symptoms first appeared for the symptom-based strategy in persons with COVID-19 who have symptoms and from 7 to 10 days after the date of their first positive test for the time-based strategy in asymptomatic persons with laboratory-confirmed COVID-19. This update was made based on evidence suggesting a longer duration of viral shedding and will be revised as additional evidence becomes available. This time period will capture a greater proportion of contagious patients; however, it will not capture everyone.
• Removed specifying use of nasopharyngeal swab collection for the test-based strategy and linked to the Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for Coronavirus Disease 2019 (COVID-19), so that the most current specimen collection strategies are recommended.

Updates as of April 4, 2020

• Revised title to include isolation in all settings other than health settings, not just home.